Cargando…

Puerarin inhibits the osteoclastogenesis by inhibiting RANKL-dependent and –independent autophagic responses

BACKGROUND: Puerarin exerts therapeutic effect on osteoporosis due to its inhibitory effect on the formation of osteoclasts. Puerarin is also widely established as an autophagy inhibitor. The study aimed to investigate the significance of autophagy in Puerarin-treated osteoclast formation. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Guoyou, Wang, Yu, Tang, Guoke, Ma, Yuanzheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6794871/ https://www.ncbi.nlm.nih.gov/pubmed/31615565 http://dx.doi.org/10.1186/s12906-019-2691-5

Ejemplares similares

Puerarin inhibits titanium particle‐induced osteolysis and RANKL‐induced osteoclastogenesis via suppression of the NF‐κB signaling pathway
por: Tang, Wenkai, et al.
Publicado: (2020)

Inhibition of RANKL-Induced Osteoclastogenesis by Novel Mutant RANKL
por: Jang, Yuria, et al.
Publicado: (2021)

The molecular mechanism of osteoclastogenesis: ODF/RANKL-dependent and independent pathways
por: Suda, T, et al.
Publicado: (2001)

Tetrandrine inhibits RANKL-induced osteoclastogenesis by promoting the degradation of TRAIL
por: Li, Jiarui, et al.
Publicado: (2022)

Sulforaphane Inhibits Osteoclastogenesis via Suppression of the Autophagic Pathway
por: Luo, Tingting, et al.
Publicado: (2021)

Pasteurella multocida Toxin Triggers RANKL-Independent Osteoclastogenesis
por: Chakraborty, Sushmita, et al.
Publicado: (2017)

Parkin Inhibits RANKL-Induced Osteoclastogenesis and Ovariectomy-Induced Bone Loss
por: Hou, Weiduo, et al.
Publicado: (2022)

Tetrandrine Prevents Bone Loss in Ovariectomized Mice by Inhibiting RANKL-Induced Osteoclastogenesis
por: Zhong, Zeyuan, et al.
Publicado: (2020)

Atorvastatin inhibits osteoclastogenesis by decreasing the expression of RANKL in the synoviocytes of rheumatoid arthritis
por: Kim, Jeong Yeon, et al.
Publicado: (2012)

Salt-inducible kinases (SIK) inhibition reduces RANKL-induced osteoclastogenesis
por: Lombardi, Maria Stella, et al.
Publicado: (2017)

Niclosamide and its derivative DK‐520 inhibit RANKL‐induced osteoclastogenesis
por: Jiao, Yurui, et al.
Publicado: (2020)

Chalcone T4 Inhibits RANKL-Induced Osteoclastogenesis and Stimulates Osteogenesis In Vitro
por: de Matos, Iolanda Augusta Fernandes, et al.
Publicado: (2023)

Dracorhodin perchlorate inhibits osteoclastogenesis through repressing RANKL‐stimulated NFATc1 activity
por: Liu, Yuhao, et al.
Publicado: (2020)

Madecassoside inhibits estrogen deficiency‐induced osteoporosis by suppressing RANKL‐induced osteoclastogenesis
por: Wang, Qingqing, et al.
Publicado: (2018)

Matrine prevents bone loss in ovariectomized mice by inhibiting RANKL-induced osteoclastogenesis
por: Chen, Xiao, et al.
Publicado: (2017)

Calycosin Suppresses RANKL-Mediated Osteoclastogenesis through Inhibition of MAPKs and NF-κB
por: Quan, Gui-Hua, et al.
Publicado: (2015)

RANKL-independent osteoclastogenesis in the SH3BP2 cherubism mice
por: Kittaka, Mizuho, et al.
Publicado: (2020)

Hippuric acid and 3‐(3‐hydroxyphenyl) propionic acid inhibit murine osteoclastogenesis through RANKL‐RANK independent pathway
por: Zhao, Haijun, et al.
Publicado: (2019)

Astilbin prevents bone loss in ovariectomized mice through the inhibition of RANKL‐induced osteoclastogenesis
por: Jin, Haiming, et al.
Publicado: (2019)

Evodiamine inhibits RANKL‐induced osteoclastogenesis and prevents ovariectomy‐induced bone loss in mice
por: Jin, Haiming, et al.
Publicado: (2018)

α-Linolenic Acid Inhibits RANKL-Induced Osteoclastogenesis In Vitro and Prevents Inflammation In Vivo
por: Deng, Yufeng, et al.
Publicado: (2023)

Nepetin inhibits osteoclastogenesis by inhibiting RANKL‐induced activation of NF‐κB and MAPK signalling pathway, and autophagy
por: Chu, Binxiang, et al.
Publicado: (2020)

Vindoline Inhibits RANKL-Induced Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss in Mice
por: Zhan, Yunfei, et al.
Publicado: (2020)

Nitazoxanide, an Antiprotozoal Drug, Reduces Bone Loss in Ovariectomized Mice by Inhibition of RANKL-Induced Osteoclastogenesis
por: Li, Chang-hong, et al.
Publicado: (2021)

Cytochalasin Z11 inhibits RANKL-induced osteoclastogenesis via suppressing NFATc1 activation
por: Wang, Lu, et al.
Publicado: (2019)

Physalin D inhibits RANKL-induced osteoclastogenesis and bone loss via regulating calcium signaling
por: Ding, Ning, et al.
Publicado: (2020)

Puerarin alleviates osteoporosis in the ovariectomy-induced mice by suppressing osteoclastogenesis via inhibition of TRAF6/ROS-dependent MAPK/NF-κB signaling pathways
por: Xiao, Long, et al.
Publicado: (2020)

Mitf Induction by RANKL Is Critical for Osteoclastogenesis
por: Lu, Ssu-Yi, et al.
Publicado: (2010)

Lipopolysaccharide- TLR-4 Axis regulates Osteoclastogenesis independent of RANKL/RANK signaling
por: AlQranei, Mohammed S., et al.
Publicado: (2021)

TRPM7 Is Essential for RANKL-Induced Osteoclastogenesis
por: Yang, Yu-Mi, et al.
Publicado: (2013)

Corrigendum: Nitazoxanide, an antiprotozoal drug, reduces bone loss in ovariectomized mice by inhibition of RANKL-induced osteoclastogenesis
por: Li, Chang-hong, et al.
Publicado: (2023)

Puerarin alleviates the ototoxicity of gentamicin by inhibiting the mitochondria-dependent apoptosis pathway
por: Niu, Ping, et al.
Publicado: (2021)

Deacylcynaropicrin Inhibits RANKL-Induced Osteoclastogenesis by Inhibiting NF-κB and MAPK and Promoting M2 Polarization of Macrophages
por: Li, Zhikun, et al.
Publicado: (2019)

Urolithin B suppresses osteoclastogenesis via inhibiting RANKL‐induced signalling pathways and attenuating ROS activities
por: Qu, Zechao, et al.
Publicado: (2022)

Inhibiting Monoacylglycerol Lipase Suppresses RANKL-Induced Osteoclastogenesis and Alleviates Ovariectomy-Induced Bone Loss
por: Liu, Hui, et al.
Publicado: (2021)

Melatonin inhibits osteoclastogenesis via RANKL/OPG suppression mediated by Rev‐Erbα in osteoblasts
por: Tian, Yihao, et al.
Publicado: (2022)

Berbamine inhibits RANKL- and M-CSF-mediated osteoclastogenesis and alleviates ovariectomy-induced bone loss
por: Qi, Guobin, et al.
Publicado: (2022)

Galangin suppresses RANKL‐induced osteoclastogenesis via inhibiting MAPK and NF‐κB signalling pathways
por: Li, Xiucheng, et al.
Publicado: (2021)

Hesperetin Prevents Bone Resorption by Inhibiting RANKL-Induced Osteoclastogenesis and Jnk Mediated Irf-3/c-Jun Activation
por: Zhang, Qiang, et al.
Publicado: (2018)

The PPAR-γ antagonist T007 inhibits RANKL-induced osteoclastogenesis and counteracts OVX-induced bone loss in mice
por: Li, Xiang, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1rbqpnsps8gfs1c9ujcn2k7k53